Azelon Pharmaceuticals
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Azelon Pharmaceuticals - overview
Established
2000
Location
-, PA, US
Primary Industry
Pharmaceuticals
About
Azelon Pharmaceuticals specializes in developing innovative pharmaceutical solutions aimed at improving patient outcomes. The company engages in research and production activities to bring effective medications to market. Azelon Pharmaceuticals is a firm founded in 2000 in the United States, focused on pharmaceutical innovations. The company has operated under a consistent business strategy, concentrating on the development of new drug formulations.
The founder's background includes previous ventures in the pharmaceutical industry, although specific details are not mentioned. They have completed four deals, with their latest funding round being a Series A amounting to USD 2. 40 mn, led by BDC Capital, bringing the total funds raised to USD 2. 40 mn.
Azelon Pharmaceuticals is dedicated to the development of pharmaceutical products that cater to diverse medical needs. Their offerings include various medications designed to treat specific health conditions, focusing on enhancing efficacy and patient compliance. The company targets a wide range of healthcare providers and patients, ensuring accessibility to their innovative therapeutic solutions. Azelon Pharmaceuticals generates revenue through the sale of its pharmaceutical products, utilizing a direct sales model to healthcare providers and institutions.
The company engages in structured pricing for its medicines, allowing them to meet the varying budgetary requirements of healthcare systems. Their revenue model is built on transactional sales, reflecting the demand for their innovative solutions in the healthcare market. Azelon Pharmaceuticals has announced plans to expand its product line with several new drug formulations expected to be launched in the coming years. The company is targeting entry into new geographic markets, specifically Europe and Asia, by the end of 2025.
Recent funding from the Series A round will be crucial in supporting these initiatives, facilitating research, development, and marketing efforts to enhance their presence in these regions.
Current Investors
Prospect Venture Partners, Lighthouse Capital Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.azelon.com
Verticals
HealthTech
Company Stage
Ceased Operations
Total Amount Raised
Subscriber access only
Azelon Pharmaceuticals - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.